Evidence map›Paper›PMID 39037155›Full record

ArticleJournal of viral hepatitis2024

Modelling the potential impact of global hepatitis B vaccination on the burden of chronic hepatitis B in the United States.

David W Hutton, Mehlika Toy, Danwei Yang, Hanwen Zhang, Senad Handanagic, Paige A Armstrong, Annemarie Wasley, Nicolas A Menzies, Hang Pham, Joshua A Salomon and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of viral hepatitis, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

David W HuttonDepartment of Health Management and Policy, University of Michigan, Ann Arbor, Michigan, USA.ORCID 0000-0001-9677-1632
Mehlika ToyAsian Liver Center, Department of Surgery, Stanford University School of Medicine, Stanford, California, USA.ORCID 0000-0001-7848-4816
Danwei YangDepartment of Health Management and Policy, University of Michigan, Ann Arbor, Michigan, USA.
Hanwen ZhangDepartment of Health Management and Policy, University of Michigan, Ann Arbor, Michigan, USA.
Senad HandanagicDivision of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.ORCID 0000-0001-8212-1153
Paige A ArmstrongDivision of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.ORCID 0000-0002-5529-8786
Annemarie WasleyGlobal Immunizations Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.ORCID 0000-0002-2542-5721
Nicolas A MenziesDepartment of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.ORCID 0000-0002-2571-016X
Hang PhamAsian Liver Center, Department of Surgery, Stanford University School of Medicine, Stanford, California, USA.ORCID 0000-0002-2480-4586
Joshua A SalomonDepartment of Health Policy, Stanford University School of Medicine, Stanford, California, USA.ORCID 0000-0003-3929-5515
Samuel K SoAsian Liver Center, Department of Surgery, Stanford University School of Medicine, Stanford, California, USA.ORCID 0000-0003-3108-086X

Funding

Intramural CDC HHS CC999999US Centers for Disease Control and Prevention 1NU38PS004651-01
6 · The paper itself

Abstract

About 80% of persons with chronic hepatitis B virus (HBV) infection in the United States are non-US-born. Despite improvements in infant hepatitis B vaccination globally since 2000, work remains to attain the World Health Organization's (WHO) global 2030 goal of 90% vaccination. We explore the impacts on the United States of global progress in hepatitis B vaccination since 2000 and of achieving WHO hepatitis B vaccination goals. We simulated immigrants with HBV infection arriving to the United States from 2000 to 2070 using models of the 10 countries from which the largest numbers of individuals with HBV infection were born. We estimated costs in the United States among these cohorts using a disease simulation model. We simulated three scenarios: a scenario with no progress in infant vaccination for hepatitis B since 2000 (baseline), current (2020) progress and achieving WHO 2030 goals for hepatitis B vaccination. We estimate current hepatitis B vaccination progress since the 2000 baseline in these 10 countries will lead to 468,686 fewer HBV infections, avoid 35,582 hepatitis B-related deaths and save $4.2 billion in the United States through 2070. Achieving the WHO 2030 90% hepatitis B infant vaccination targets could lead to an additional 16,762 fewer HBV infections, 989 fewer hepatitis B-related deaths and save $143 million through 2070. Global hepatitis B vaccination since 2000 reduced prevalence of HBV infection in the United States. Achieving the WHO 2030 infant vaccination goals globally could lead to over one hundred million dollars in additional savings.

Indexed as

Global HealthHepatitis B, ChronicHepatitis B VaccinesVaccinationAdolescentAdultAgedAged, 80 and overChildChild, PreschoolCost of IllnessEmigrants and ImmigrantsFemaleHumansInfantInfant, NewbornHepatitis B Vaccineseconomicshepatitis BvaccinationWorld Health Organization

Identifiers

PMID39037155
PMCPMC11534504

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.